SoracteLite TPLA

The new non-surgical laser treatment for Benign Prostatic Hyperplasia

SoracteLite

The new non-surgical laser treatment for Benign Prostatic Hyperplasia

What is SoracteLite TPLATM?

SoracteLite TPLATM is an innovative and micro-invasive treatment for BPH. It is a non-surgical procedure which, by exploiting laser energy, obtains a significant reduction in the volume of the prostate consequently freeing up the urethral channel from the compressive processes that obstruct normal urinary flow. This ensures a gradual resolution of symptoms and progressive improvement in the quality of life for the patient, who will urinate less frequently with a more powerful flow, while the number of night-time urinations is reduced or eliminated, and the risk of urinary tract infections decreases.

sontex are exported all over the world and different industries with quality first. Our belief is to provide our customers with more and better high value-added products. Let's create a better future together.

SoracteLite TPLATM is an alternative treatment to surgery and other mini-invasive techniques that use a transurethral approach. It differs from these by the treatment methods (in-situ thermal ablation without tissue removal), absence of complications involving the urethra, reduced hospitalisation (day hospital procedure), and rapid recovery of the patient (few hours after treatment).

The micro-invasiveness and safety of the treatment are guaranteed by the following aspects:

• Type of approach: SoracteLite TPLATM is the only treatment that uses a transperineal approach (Transperineal Laser Ablation TPLATM), with the insertion of very thin needles to reach the area to be treated, thus avoiding traumatic interactions with the last section of the urinary tract (urethra and bladder) and the complications often associated with the transurethral approach.
• No prostate tissue removal: laser energy is applied directly inside the prostate, causing a coagulation of the tissue which, being naturally reabsorbed by the gland, causes a volumetric reduction, thus preserving its anatomy and functionality.
• Non-surgical treatment: it drastically reduces the complications related to surgery such as bleeding, infections, impotence and retrograde ejaculation, and it also makes it possible to treat patients suffering from coagulation disorders who are on anticoagulant therapy that cannot be suspended or modified.
• No general or loco-regional (spinal) anaesthesia: the SoracteLite TPLATM treatment is performed under local anaesthesia, thus avoiding the risks associated with anaesthetic procedures.

SoracteLite TPLATMis an innovative treatment, still not widely used, although rapidly expanding in Italy and abroad. SoracteLite TPLATM is often compared to other treatments using laser technology (and that are better-known as they have been on the market for several years), such as green laser, thulium or holmium laser. These are all treatments which, unlike SoracteLite TPLATM, involve an invasive and destructive surgical approach to the organ.

How it works

SoracteLite TPLATM uses low power laser energy(typically 3 Watts) for few minutes: laser radiation is transmitted by means of optical fibres inserted percutaneously in the organ through extremely thin needles with a gauge of less than one millimetre. The portion of thermally treated tissue is naturally reabsorbed by the gland in the following weeks, resulting in a reduction in the prostate volume and the resolution of symptoms.

Results

Treatment effectiveness is demonstrated by the resolution of symptoms and an improvement in the quality of life of the patients treated. The monitoring of the patients has shown that the SoracteLite TPLATM treatment is beneficial in just a few days and that the improvement is stable over time. However, it is recommended that patients with the typical symptomatology of Benign Prostatic Hyperplasia talk to a specialist who can make a conclusive diagnosis. Once the diagnosis has been established, the doctor will decide the best therapy.

TUESDAY, Oct. 3, (HealthDay News) — Minimally invasive transperineal laser ablation (TPLA) of the prostate appears effective for benign prostatic hyperplasia (BPH), according to a review published online Sept. 21 in Therapeutic Advances in Urology.

For more information, please visit what is tpla.

Lazaros Tzelves, from the University College London Hospitals, and colleagues conducted a systematic literature review to examine the safety and efficacy of TPLA for BPH.

Based on 11 included studies, the researchers found that functional outcomes were improved in the majority of studies both for objective (maximum flow rate and postvoid residual) and subjective outcomes (improvement of International Prostate Symptom Score and quality of life). Complications included hematuria (range: 1.9 to 2.3 percent), dysuria (3.7 to 36.3 percent), acute urinary retention (1.9 to 19 percent), orchitis/urinary tract infections (0.6 to 9.1 percent), and prostatic abscess formation (0.6 to 4.8 percent). The vast majority of patients (>95 percent) retained their ejaculation, while erectile function was maintained or improved.

“TPLA of the prostate is an innovative, minimally invasive technique for managing patients with BPH,” the authors write. “Existing studies indicate an effective technique in reducing International Prostate Symptom Score and quality of life scores, postvoid residual reduction, and increase in Qmax [maximum urinary flow rate], albeit the measured improvements in terms of Qmax are not equal to transurethral resection of the prostate.”

Abstract/Full Text

Are you interested in learning more about Biodegradable Forks and Knives? Contact us today to secure an expert consultation!